A brand new drug might be more effective at preventing HIV than current methods. Many people take daily oral antiretroviral medication—known as PrEP (pre-exposure prophylaxis)—to protect themselves ...
A new HIV antiretroviral shows promise as a long-acting, oral prophylactic agent, according to a new study by Izzat Raheem, Tracy Diamond and colleagues from Merck & Co., Inc., Rahway, NJ, USA, ...
HIV Virus Creative artwork featuring colorized 3D prints of HIV virus particles. The virus surface (red) is covered with proteins (dark blue) that enable the virus to enter and infect human cells, and ...
Subdermal delivery of antiretrovirals shows promise in early trials Researchers at the University of California, San Francisco, have found that pre-exposure prophylaxis can be effective in preventing ...
Postexposure HIV prophylaxis has been recommended for men who have sex with men, but the window to start treatment is short (72 hours) and evidence for its efficacy is limited. The recent Pre-exposure ...
In June, the U.S. Food and Drug Administration (FDA) approved Gilead Sciences, Inc.'s (NASDAQ:GILD) Yeztugo (lenacapavir) as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV ...
MONTRÉAL, March 25, 2025 /CNW/ - ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. (PFE) and Shionogi as shareholders, is pleased to ...
The federal government says consignments of Lenacapavir, a new drug for HIV prevention, are expected to arrive in Nigeria in March ...
The federal government has announced that a new drug for HIV prevention, Lenacapavir, will arrive in Nigeria in March 2026.
Nigeria is set to receive its first consignments of the landmark Lenacapavir, a new HIV prevention medicine, in March 2026, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results